Get the Stockscreener App
81.05
3.66%
3.23
Apogee Therapeutics Inc stock is traded at $81.05, with a volume of 493.69K.
It is up +3.66% in the last 24 hours and down -1.66% over the past month.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$77.82
Open:
$78.22
24h Volume:
493.69K
Relative Volume:
0.54
Market Cap:
$6.10B
Revenue:
-
Net Income/Loss:
$-274.62M
P/E Ratio:
-18.73
EPS:
-4.3278
Net Cash Flow:
$-235.37M
1W Performance:
-0.60%
1M Performance:
-1.66%
6M Performance:
+12.09%
1Y Performance:
+114.06%
1-Day Range:
$77.00
$80.96
1-Week Range:
$75.86
$85.99
52-Week Range:
$34.34
$95.31
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
80.95 | 5.87B | 0 | -274.62M | -235.37M | -4.3278 |
VRTX
Vertex Pharmaceuticals Inc
|
447.44 | 113.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.83 | 65.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
834.01 | 52.14B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
299.87 | 40.73B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.70 | 32.87B | 742.00K | -1.37B | -1.07B | -7.0731 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Hold |
| Jan-22-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-07-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
(APGE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Apogee Therapeutics to Participate in Upcoming June Conferences - The Manila Times
Hear Apogee Therapeutics' June fireside talks at Jefferies and Goldman - Stock Titan
Apogee Therapeutics: Charging Toward Pivotal Eczema Trial With Extended Dosing (APGE) - Seeking Alpha
Apogee Therapeutics lines up $1.3B strategic financing for zumilokibart program - Proactive financial news
Blackstone injects up to $1.3 billion into Apogee skin drug - MSN
Apogee Therapeutics Soars After $1.3B Deal with Blackstone Life Sciences - StockInvest.us
Apogee Therapeutics Advances Eczema Drug Zumilokimab to Phase 3 Trials - geneonline.com
Apogee Therapeutics’ Phase 2 APEX Trial Assesses Zumilokibart Dosage Optimization for Atopic Dermatitis Over 16 Weeks - geneonline.com
Apogee orbiting big AD market as Apex phase II data land - BioWorld News
Blackstone Backs Apogee With Up To $1.3 Billion - GuruFocus
Young biotech Apogee lands $1.3B deal that is called 'largest royalty financing' of its kind - The Business Journals
Latham Advises Apogee Therapeutics in Strategic Financing Collaboration - Latham & Watkins LLP
Apogee secures up to $1.3 billion from Blackstone to advance eczema drug - Reuters
Truist cuts Apogee Therapeutics stock price target on valuation By Investing.com - Investing.com India
Apogee Therapeutics (APGE) falls after new eczema trial data as investors digest results - Quiver Quantitative
Truist cuts Apogee Therapeutics stock price target on valuation - Investing.com
Apogee falls following phase 2 results for zumilokibart in atopic dermatitis - Seeking Alpha
Blackstone Life Sciences commits up to $1.3B to fund Waltham biotech's drug - The Business Journals
Apogee’s zumilokibart meets Phase 2 trial endpoints in dermatitis - Investing.com UK
Apogee Investors React to $1.3 Billion Blackstone Royalty Deal Despite Positive Zumilokibart Trial Results in Atopic Dermatitis - geneonline.com
Apogee Therapeutics, Inc. announced that it expects to receive $500 million in funding - marketscreener.com
With $1.3B in new funding, Apogee gears up for pivotal zumilokibart studies in dermatitis - FirstWord Pharma
Apogee Therapeutics Potential Atopic Dermatitis Treatment Meets Primary, Secondary Endpoints in Mid-Stage Trial - Moomoo
Apogee Therapeutics (APGE) Shares Drop Following $1.3B Financing Deal - GuruFocus
APGE: Zumilokibart's phase II data show strong efficacy, safety, and reduced injection burden in atopic dermatitis - TradingView
Apogee Stock Slides After Blackstone Financing Deal And Positive Drug Data - Benzinga
APGE: Mid-dose zumilokibart showed strong efficacy and safety, enabling phase III and broader development - TradingView
Apogee Therapeutics IncBlackstone Life Sciences to pay $100 million upfront for revenue share on Zumilokibart salesSEC filing - marketscreener.com
Wedbush Raises Price Target on Apogee Therapeutics to $135 From $120, Keeps Outperform Rating - Moomoo
Apogee Therapeutics secures $1.3 billion Blackstone financing deal, shares dive - Investing.com Nigeria
Apogee secures up to $1.3 billion financing from Blackstone By Investing.com - Investing.com India
Apogee enters $1.3 billion strategic financing collaboration - The Pharma Letter
Apogee’s zumilokibart meets Phase 2 trial endpoints in dermatitis By Investing.com - Investing.com Nigeria
Apogee Therapeutics Shares Surge Following $1.3 Billion Blackstone Financing Partnership (APOG) - Yahoo Finance
Apogee Therapeutics Secures Major Non-Dilutive Blackstone Financing - TipRanks
APGE: Zumilokibart achieved 65.9% EASI-75 at 16 weeks with low injection burden and strong safety - TradingView
Apogee Therapeutics shares jump on $1.3B Blackstone deal By Investing.com - Investing.com Nigeria
Apogee Therapeutics shares jump on $1.3B Blackstone deal - Investing.com
Apogee Therapeutics (Nasdaq: APGE) secures up to $1.3B from Blackstone - Stock Titan
[8-K] Apogee Therapeutics, Inc. Reports Material Event - Stock Titan
Apogee Therapeutics Announces $1.3 Billion Strategic - GlobeNewswire
Eczema trial cuts injections with zumilokibart as Blackstone backs Apogee - Stock Titan
Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026 - GlobeNewswire
APGE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Certain Stock Options of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2026. - marketscreener.com
Certain Restricted Stock Units of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2026. - marketscreener.com
BofA Securities Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $131 - Moomoo
Apogee Therapeutics: Targeting Atopic Dermatitis (NASDAQ:APGE) - Seeking Alpha
Apogee Therapeutics Insider Sold Shares Worth $1,641,711, According to a Recent SEC Filing - Moomoo
How (APGE) Movements Inform Risk Allocation Models - Stock Traders Daily
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.54%
2.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):